ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study

CAR-T has transformed relapsed/refractory LBCL treatment, with CD28-based products yielding rapid responses but higher ICANS rates. With Axicabtagene-ciloleucel and Brexucabtagene-autoleucel, overall and severe ICANS reach 78% and 35%, respectively. Older adults are vulnerable, yet mitigation strat...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Gil Fridberg, Odelia Amit, Yehonathan Sherf, Chava Perry, Yair Herishanu, Erel Joffe, Tamir Shragai, Roy Vitkon, Meir Preis, Shoshan Perk, Nadav Sarid, Sharon Ben Barouch, Ronit Gold, Chen Glait-Santar, Irit Avivi, Ron Ram
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Ferrata Storti Foundation 2026-02-01
Serie:	Haematologica
Accesso online:	https://haematologica.org/article/view/13156
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!